Our Vision

​

The vision for JE PolyDesign is to provide chemical tools to help making oncology therapeutics more efficient and accessible for everyone.  

​

The HEMI-Link™-Technology Platform

​

JE PolyDesign provide new and  enabling maleimide-linker chemistry, i.e., the HEMI-Link™-Technology platform, to meet current challenges regarding the development of next generation "Antibody-Drug Conjugates" (ADC's), applicable for oncology therapeutics.

​

Antibody-Drug Conjugate (ADC) Chemistry

​

ADC chemistry is one of the fastest growing research areas for selective treatment of cancer. The market value by 2022 is estimated to reach $18 Billion. Chemistry challenges and limitations for faster advancement of this research, and for the development of the final pharmaceuticals, are:

​

• Limited molecular design flexibility

• Availability and purity of raw materials

• Chemical complexity

• Access to variable and controllable linker chemistry

​

The HEMI-Link™-Technology platform addresses the challenges listed above based on new and enabling maleimide-linker chemistry. Specifically, design of the R-group in the chemical ADC structure as shown below is one key target to reach success:

​

​

 

 

 

 

Our maleimide-linker platform is more flexible and simple than existing choices, and we aim to create opportunity to design novel ADC's with characteristics and properties controllable by R, such as:

​

• Controlled drug release

• Limit/eliminate deconjugation leading to off-target toxicity

• Hydrophilicity/hydrophobicity 

• Solubility and pH-stability

​

Collaborative partnerships are essential for success in this complicated field of science, and we are actively exploring such opportunities. 

​

​

​

​

​